(Q36947707)

17 August 2017

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes (English)

1 reference

17 August 2017

Yang Lu

1

1 reference

17 August 2017

Jason R Slizgi

2

1 reference

17 August 2017

Kenneth R Brouwer

3

1 reference

17 August 2017

Robert L St Claire

4

1 reference

17 August 2017

Kimberly M Freeman

5

1 reference

17 August 2017

Maxwell Pan

6

1 reference

17 August 2017

William J Brock

7

1 reference

17 August 2017

Kim L Brouwer

8

1 reference

17 August 2017

24 March 2016

1 reference

Drug Metabolism and Disposition

17 August 2017

1 reference

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Tolvaptan for the treatment of liver cirrhosis oedema

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Oral tolvaptan is safe and effective in chronic hyponatremia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Prediction of hepatic clearance in human from in vitro data for successful drug development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4885486

Cytochrome p450 inhibitory properties of common efflux transporter inhibitors

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27013400

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27013400

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27013400

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1124/DMD.115.067629

0 references

1 reference

17 August 2017

PubMed publication ID

27013400

1 reference